Biomimetic Targeted Theranostic Nanoparticles for Breast Cancer Treatment
5
item.page.dc.date.issued
2022-10-01
item.page.dc.type
item.page.dc.identifier.eissn
14203049
item.page.dc.identifier.doi
item.page.dc.identifier.scopus
2-s2.0-85139868702
item.page.dc.identifier.pmid
36235009
item.page.oaire.citation.title
Molecules
item.page.oaire.citation.volume
27
item.page.oaire.citation.issue
19
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Molecules Vol.27 No.19 (2022)
punsarn.item.page.citation
Marshall S.K., Angsantikul P., Pang Z., Nasongkla N., Hussen R.S.D., Thamphiwatana S.D. Biomimetic Targeted Theranostic Nanoparticles for Breast Cancer Treatment. Molecules Vol.27 No.19 (2022). doi:10.3390/molecules27196473 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/83596
item.page.dc.title
Biomimetic Targeted Theranostic Nanoparticles for Breast Cancer Treatment
item.page.dc.contributor.author
item.page.oairecerif.author.affiliation
item.page.dc.contributor.other
item.page.dc.description.abstract
The development of biomimetic drug delivery systems for biomedical applications has attracted significant research attention. As the use of cell membrane as a surface coating has shown to be a promising platform for several disease treatments. Cell-membrane-coated nanoparticles exhibit enhanced immunocompatibility and prolonged circulation time. Herein, human red blood cell (RBC) membrane-cloaked nanoparticles with enhanced targeting functionality were designed as a targeted nanotheranostic against cancer. Naturally, derived human RBC membrane modified with targeting ligands coated onto polymeric nanoparticle cores containing both chemotherapy and imaging agent. Using epithelial cell adhesion molecule (EpCAM)-positive MCF-7 breast cancer cells as a disease model, the nature-inspired targeted theranostic human red blood cell membrane-coated polymeric nanoparticles (TT-RBC-NPs) platform was capable of not only specifically binding to targeted cancer cells, effectively delivering doxorubicin (DOX), but also visualizing the targeted cancer cells. The TT-RBC-NPs achieved an extended-release profile, with the majority of the drug release occurring within 5 days. The TT-RBC-NPs enabled enhanced cytotoxic efficacy against EpCAM positive MCF-7 breast cancer over the non-targeted NPs. Additionally, fluorescence images of the targeted cancer cells incubated with the TT-RBC-NPs visually indicated the increased cellular uptake of TT-RBC-NPs inside the breast cancer cells. Taken together, this TT-RBC-NP platform sets the foundation for the next-generation stealth theranostic platforms for systemic cargo delivery for treatment and diagnostic of cancer.